Introduction

Survival of patients with symptomatic esophageal adenocarcinoma (EAC) is poor (1,2). Strategies that prevent cancer by eradicating Barrett's esophagus (BE) with dysplasia, or detect cancer at an early, curable stage have been implemented to reduce cancer mortality. Screening is the process by which asymptomatic populations are tested to identify individuals who have early-stage cancer or a pre-malignant condition that predisposes them to develop cancer. High-risk individuals identified through screening either undergo treatment of cancer (or the pre-malignant condition) or surveillance, in which testing is repeated to identify disease at a curable stage. Guidelines from national societies recommend screening in selected populations and surveillance for those who have BE; however, there is controversy about who to screen, what tests to use, how to perform surveillance and when to treat (3,4).

This chapter summarizes the results of two independently conducted systematic reviews of the published literature.
adenocarcinoma, Barrett esophagus, dysplasia, and endoscopic surveillance to query MEDLINE, Cochrane CENTRAL, SCOPUS, Web of Science, PubMed and Ovid EMBASE (6). Of 1,747 records identified through this query, 1,631 were excluded due to lack of relevance to the study question [1,419] or format of a narrative review or editorial [212]. The remaining 116 publications were screened and an additional 97 studies were excluded due to the lack of: inclusion of the outcome of interest [50], appropriate comparison group [44], data for the comparison group [1], or human subjects [2]. Of the 116 full text articles reviewed, 19 met all inclusion and exclusion criteria for this meta-analysis.

This chapter further excludes from discussion studies from either systematic review for which the benefit of endoscopy on EAC mortality could not be ascertained due to the absence of the predictor or outcome variables, or the combination of endpoints (such as combining high-grade dysplasia and cancer). Combined, these systematic reviews describe 16 studies for which cancer mortality can be compared between individuals undergoing screening and/or surveillance endoscopy with individuals not receiving endoscopy (Table 1).

The effectiveness of endoscopic screening and surveillance to reduce EAC mortality

Due to the barriers based on the size and duration needed to conduct a properly powered randomized controlled trial, the evidence supporting the use of screening and surveillance to reduce mortality from EAC cancer is limited to case-control or cohort studies. A typical case-control study compares patients who died of cancer with controls who either did not have cancer or did not die of cancer. After ascertaining the outcome of each patient in the study (i.e., whether they died of EAC), investigators examine records to determine which patients underwent screening or surveillance endoscopy prior to the cancer diagnosis. However, in a case-control study the prevalence of cancers is set by the study design and is a function of the ratio of cases to controls. Because of this, a case-control study does not calculate the cancer mortality reduction associated with screening (i.e., the risk ratio). Instead, case-control studies provide an “odds ratio”, which is the odds that a patient who died of cancer underwent a prior endoscopy compared with the odds that a patient who did not have cancer (or had cancer but did not die of cancer) had a prior endoscopy. It is reassuring, though, that for diseases with a low incidence rate (e.g., 1% or lower as is the case with esophageal cancer) the odds ratio (OR) approximates the risk ratio and is a good estimate of the cancer mortality reduction associated with endoscopic screening and surveillance.

A cohort study, which can be prospective or retrospective, is another study design that can estimate the effectiveness of endoscopic screening and surveillance on cancer mortality. This type of study follows a group of patients with BE (cohort) over time to determine the incidence and mortality from cancer. Individuals who receive endoscopic screening and surveillance are compared with those who do not receive endoscopy to calculate the hazard ratio, or the incidence of cancer in patients who receive endoscopy divided by the incidence in those who do not receive endoscopy. The advantage of the cohort study compared with a case-control study is that the incidence of cancer is observed in a cohort study, allowing the reduction in cancer risk to be calculated with endoscopic screening and surveillance. The barriers to a cohort study include identifying an adequately sized cohort, following patients long enough to observe cancer development, and incomplete data due to drop-out of patients from the cohort.

Non-randomized studies have a higher risk of bias than randomized controlled trials. Selection bias occurs because individuals who undergo endoscopy are usually healthier and therefore more likely to live longer than individuals who do not undergo endoscopy. Lead-time bias may also be present, which represents a longer observed survival with screening due to detection of pre-clinical cancer. Length-time bias can occur when there is heterogeneity in the natural history of cancer. Slowly growing cancers are more likely to be detected since they span several surveillance intervals compared with rapidly growing cancers that may arise between surveillance intervals. This creates the appearance that endoscopic surveillance prolongs survival when the truth is that cancers diagnosed by surveillance are more indolent. Statistical techniques are employed to mitigate the effects of bias, but it is difficult to identify and adjust for all sources of bias in non-randomized studies.

The effectiveness of endoscopic surveillance

Early outcomes studies in the 1990’s and early 2000’s using a retrospective cohort study design reported that endoscopic surveillance could reduce EAC mortality. Patients with EAC who had undergone endoscopic surveillance had significantly better survival than patients who had not
undergone endoscopy (19-22). These studies, however, used limited statistical techniques that could not adjust for the potential biases of the retrospective design.

In a retrospective cohort study using more advanced statistical methods, Cooper et al. reported that patients who had an upper endoscopy at least one year prior to the cancer diagnosis had 27% lower cancer mortality than patients with EAC who did not have endoscopy [hazards ratio (HR), 0.73; 95% confidence interval (CI): 0.57–0.93] (17). Using a different data set but similar study design, Corley and others reported an 80% reduction in cancer death in patients with EAC who had undergone endoscopic surveillance compared

<table>
<thead>
<tr>
<th>Author</th>
<th>Design</th>
<th>Population</th>
<th>Surveillance definition</th>
<th>Outcome</th>
<th>Cancer mortality reduction (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tramontano 2017</td>
<td>Cohort</td>
<td>EAC</td>
<td>BE diagnosis &gt;6 months prior to cancer</td>
<td>HR</td>
<td>0.49 (0.43–0.55)</td>
</tr>
<tr>
<td>El-Serag 2016</td>
<td>Cohort</td>
<td>BE with EAC</td>
<td>EGD for surveillance</td>
<td>HR</td>
<td>0.47 (0.35–0.64)</td>
</tr>
<tr>
<td>Kastelein 2016</td>
<td>Cohort</td>
<td>EAC*</td>
<td>EGD for surveillance</td>
<td>HR</td>
<td>0.8 (0.3–1.8) stage 0 EAC; HR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.7 (0.4–1.2) stage 1 EAC; neither significant</td>
</tr>
<tr>
<td>Royston 2016</td>
<td>Cohort</td>
<td>BE (with or without intestinal</td>
<td>EGD for surveillance</td>
<td>HR</td>
<td>0.64 (0.30–1.48), not significant</td>
</tr>
<tr>
<td>Bhat 2015</td>
<td>Cohort</td>
<td>EAC</td>
<td>BE diagnosis &gt;6 months prior to cancer</td>
<td>HR</td>
<td>0.39 (0.27–0.58)</td>
</tr>
<tr>
<td>Verbeek 2014</td>
<td>Cohort</td>
<td>EAC</td>
<td>EGD for surveillance</td>
<td>HR</td>
<td>0.79 (0.64–0.92)</td>
</tr>
<tr>
<td>Corley 2013</td>
<td>Case-Control</td>
<td>Cases: EAC or EGJ cancer death; controls: BE</td>
<td>EGD for surveillance ≤3 years prior to cancer</td>
<td>OR</td>
<td>0.99 (0.36–2.75), no improved survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EAC</td>
<td>EGD or BE diagnosis 6 months–3 years prior to cancer</td>
<td>HR</td>
<td>EGD 0.66 (0.47–0.93); BE 0.045 (0.25–0.80)</td>
</tr>
<tr>
<td>Rubensteini 2008</td>
<td>Cohort</td>
<td>EAC or gastric cardia adenocarcinoma</td>
<td>EGD 1–5 years prior to cancer</td>
<td>HR</td>
<td>0.93 (0.58–1.50), no improved survival</td>
</tr>
<tr>
<td>Kearney 2003</td>
<td>Case-Control</td>
<td>Cases: EAC or gastric cardia cancer death; Controls: GERD</td>
<td>EGD ≥1 year prior to cancer</td>
<td>OR</td>
<td>0.66 (0.45–0.96)</td>
</tr>
<tr>
<td>Cooper 2002</td>
<td>Cohort</td>
<td>EAC or gastric cardia adenocarcinoma (separate)</td>
<td>EGD ≥1 year prior to cancer</td>
<td>HR</td>
<td>EAC 0.73 (0.57–0.93); cardia not significant</td>
</tr>
<tr>
<td>Cooper 2002</td>
<td>Cohort</td>
<td>EAC or gastric cardia adenocarcinoma</td>
<td>EGD for surveillance</td>
<td>HR</td>
<td>0.2 (0.1–0.7)</td>
</tr>
<tr>
<td>Incarbone 2002</td>
<td>Cohort</td>
<td>EAC</td>
<td>EGD for surveillance</td>
<td>Median survival</td>
<td>48 vs. 24 months (P&lt;0.01)</td>
</tr>
<tr>
<td>Ferguson 2002</td>
<td>Cohort</td>
<td>EAC</td>
<td>EGD</td>
<td>Median survival</td>
<td>107 vs. 12 months (P&lt;0.001)</td>
</tr>
<tr>
<td>van Sandick 1998</td>
<td>Cohort</td>
<td>EAC or EGJ adenocarcinoma</td>
<td>BE diagnosis ≥6 months prior to cancer</td>
<td>Cancer mortality</td>
<td>85.9% vs. 43.3%, log rank P=0.0029 (significantly better)</td>
</tr>
<tr>
<td>Peters 1994</td>
<td>Cohort</td>
<td>EAC cardia not specified</td>
<td>EGD</td>
<td>Cancer mortality</td>
<td>Chi² =5.8, significantly better</td>
</tr>
</tbody>
</table>

*, comparison between observed and expected survival. EAC, esophageal adenocarcinoma; EGJ, esophago-gastric junction; GERD, gastroesophageal reflux disease; BE, Barrett’s esophagus; EGD, esophagogastroduodenoscopy; HR, hazards ratio; OR, odds ratio; CI, confidence interval.
with no surveillance (18). Kearney et al. reported that individuals with symptoms of gastroesophageal reflux who had received an upper endoscopy greater than one year prior to the diagnosis of EAC patients had a 34% lower incidence of cancer mortality (OR, 0.66; 95% CI: 0.45–0.96) (16).

The indication for upper endoscopy was not known in these studies since administrative or billing data were used to identify endoscopy use. Thus, it is not clear that all upper endoscopies were performed for surveillance since they could have been performed in response to symptoms or signs related to esophageal cancer. To address this limitation, Cooper and colleagues conducted a cohort study of patients with EAC, using the diagnosis of BE 6 months to 3 years prior to development of EAC as a surrogate for surveillance endoscopy (14). Using this surrogate could reduce the risk that endoscopy was performed for persistent reflux symptoms that would identify a group of individuals at higher risk of cancer, or for symptoms of cancer itself. They found that individuals diagnosed with BE prior to developing cancer were 55% less like to die of cancer compared with patients who did not have a prior diagnosis of BE.

Using retrospective cohort designs, subsequent studies have demonstrated prolonged cancer survival among patients who were undergoing endoscopic surveillance. Verbeek reported a 21% reduction in death from cancer among patients with BE who underwent endoscopic surveillance compared with those who did not undergo endoscopy (12). Similar to the Cooper study of the benefit of a prior diagnosis of BE, Bhat and others reported that having a diagnosis of BE before receiving a diagnosis of cancer was associated with 61% reduction in cancer death (HR, 0.39; 95% CI: 0.27–0.58) (11). El-Serag published a cohort study of patients with BE who developed EAC during a mean follow up of five years (8). Patients in whom endoscopic surveillance was conducted, identified through manual chart abstraction, had lower cancer mortality compared with patients who did not undergo surveillance endoscopy (34% vs. 54%; P<0.0001). A significant benefit of surveillance endoscopy on cancer mortality was demonstrated even after adjustment for age, race, comorbidity, year of cancer diagnosis, number of clinic visits, and the propensity to undergo upper endoscopy with a HR of 0.47 (95% CI: 0.35–0.64). The benefit of surveillance was largely explained by diagnosis at a lower stage of cancer plus the increased likelihood of cancer treatment among patients who received surveillance.

However, there are additional studies that have not demonstrated a benefit from endoscopic surveillance. Kastelein reported that compared with national cancer statistics there was no difference in cancer death among a cohort of patients with BE undergoing surveillance (9). In a follow-up to their earlier cohort study, Corley et al. published a study comparing patients with BE who died of EAC with controls with BE who did not die of EAC (13). In contrast to their prior findings, they reported that endoscopy within three years of a diagnosis of EAC did not prolong survival. While patients with EAC were less likely to have undergone prior endoscopy, this finding was not statistically significant.

Rubenstein also reported no improvement in survival among patients receiving endoscopy in a retrospective cohort study of patients with EAC (HR, 0.93; 95% CI: 0.58–1.50) (15). A unique aspect of this study was a seven-year follow-up period after the cancer diagnosis. A secondary analysis limiting the follow up to five years found a significant mortality benefit from endoscopy, suggesting that lead-time bias could be a problem with studies using a shorter follow-up.

Tramontano et al. identified almost 5,000 patients with EAC in linked SEER-Medicare data to determine whether a diagnosis of BE as proxy for endoscopic screening and surveillance was associated with reduced cancer mortality (7). After adjusting for potential confounders (age, sex, race, year of cancer diagnosis, geographic region, marital status, income, education level, comorbidities, and treatment), the hazards of cancer-related death was reduced among patients with a prior diagnosis of BE (HR, 0.49; 95% CI: 0.43–0.55). Inclusion of cancer stage and type of treatment in the hazards model should eliminate the mortality benefit since these are the two plausible mechanisms through which cancer mortality could be reduced with endoscopic screening and surveillance; however, despite inclusion of these factors the benefit of a prior Barrett’s diagnosis remained, suggesting residual confounding. Further analysis incorporating correction for lead-time bias reduced the observed mortality benefit to non-significant values (HR, 0.89; 95% CI: 0.78–1.01). Their conclusion was that patients with EAC with a prior diagnosis of BE have better overall- and cancer-specific survival compared with cancer patients who do not have a prior diagnosis of BE and presumably do not undergo screening or surveillance. However, their detailed analysis revealed that much of the observed benefit could be a result of lead and/or length time bias, reducing our confidence that screening and surveillance reduced cancer mortality.
The difference in outcomes reported between studies may be explained by the limitations in their study design. The best study to determine the effectiveness of endoscopic screening to decrease mortality of EAC would be performed in a group of people who did not know whether they had BE: these individuals would be randomized to undergo endoscopy or no endoscopy. Endoscopy would identify patients with BE who would undergo surveillance endoscopy at intervals based on the presence or absence of dysplasia, or other markers of increased cancer risk. All patients would be followed for a duration sufficient to observe cancer incidence and mortality. Patients with dysplasia or early cancer would undergo endoscopic eradication therapy and esophagectomy would be performed in patients with malignancy extending beyond the mucosa. The primary outcome of this study would be a comparison of cancer mortality between individuals randomized to screening with individuals randomized to no screening. Secondary endpoints would include cancer incidence, stage at the time of diagnosis, and overall mortality between the two groups.

There is an ongoing multicenter clinical trial in the United Kingdom of 3,400 patients diagnosed with BE randomized to endoscopic surveillance every 2 years, or non-surveillance (or “at need” endoscopy in response to clinical symptoms or signs). While the benefit of screening to detect BE will remain elusive, this powerful study is expected to provide evidence to support or refute the benefits of endoscopic surveillance among individuals diagnosed with BE on esophageal cancer incidence and mortality (23).

An important consideration of the discussed studies was that they used data collected prior to the widespread use of endoscopic radiofrequency ablation (RFA) (24-26). Photodynamic therapy (PDT) may have been available, but its use was limited (27,28). The role of surveillance prior to the availability of endoscopic eradication therapy was to diagnose cancer at a stage amenable to cure. In contrast, current endoscopic eradication therapy aims to treat cancer precursors such as dysplasia with the aim of reducing cancer incidence. Future cohort studies may determine the effectiveness of surveillance when endoscopic eradication is used to treat neoplasia and early stage cancer.

Cost-effectiveness of endoscopic surveillance in patients with BE

Other chapters in this review will cover the effectiveness of endoscopic eradication therapy for patients with BE and low- or high-grade dysplasia. The focus of this chapter is on the benefit of surveillance, limiting the scope of this discussion to the point where surveillance identifies a lesion that should trigger treatment. Since there are no clinical studies available to answer this question, we rely on other means to estimate the relative benefits of surveillance versus therapy for patients who develop a treatable lesion. One quantitative tool available to compare different options for medical management is medical decision analysis. A specialized version of decision analysis is a cost-effectiveness analysis (CEA) that allows comparison of the benefits of competing strategies in relation to the resources needed to implement the strategies (29-31).

This chapter summarizes the results of a systematic review of English language publications in PubMed conducted from August 2001 through August 2016 using MESH terms including BE; esophageal neoplasms diagnosis; health care economics and organizations. Studies were included if they reported both the costs and the effectiveness of endoscopic surveillance and used metrics of life-years or quality-adjusted life-years gained.

Surveillance versus endoscopic therapy for high grade dysplasia (HGD)

Due to the high rate of stricture after PDT, endoscopic mucosal resection for nodular dysplasia followed by RFA of flat mucosa has become the preferred method of endoscopic treatment for BE with HGD. This strategy is associated with fewer complications than esophagectomy, is highly effective in eradicating dysplasia and metaplasia and has a low rate of dysplasia recurrence (3,4). Six studies reported the cost-effectiveness of RFA for HGD compared with endoscopic surveillance with esophagectomy for cancer (Table 2) (32-37). In all studies, RFA with or without endoscopic mucosal resection yielded more quality-adjusted life-years gained at a lower cost than surveillance with esophagectomy for cancer.

Surveillance versus endoscopic eradication therapy for low grade dysplasia (LGD)

Optimal management of patients with BE and low-grade dysplasia is controversial (Table 3). Analyses conducted prior to the advent of endoscopic eradication therapy found that endoscopic surveillance for LGD was cost-effective compared with no surveillance or esophagectomy; however,
the optimal surveillance interval was unclear (40,41). Kastelein et al. analyzed a variety of surveillance intervals for BE and LGD, with patients undergoing endoscopic eradication therapy for a diagnosis of HGD. Surveillance endoscopy every 3 years among patients with BE and LGD was cost-effective (€32,000 per QALY gained); however, annual surveillance was also within the willingness-to-pay threshold. Similarly, Gordon et al. estimated that surveillance of non-dysplastic BE every three years for non-dysplastic Barrett’s and annually for patients with LGD was cost-effective (38).

Endoscopic ablation of non-dysplastic BE

Endoscopic eradication therapy for non-dysplastic BE is not a cost-effective strategy. The most recent economic analysis by Hur et al. reported that endoscopic eradication therapy for patients with BE without dysplasia costs between $118,000 and $205,000 per QALY gained compared with surveillance, reserving therapy for patients who develop low- or high-grade dysplasia (34). For the foreseeable future, endoscopic surveillance of non-dysplastic BE with endoscopic ablation for dysplasia remains a more cost-effective strategy (Table 3).

Table 2 Cost-effectiveness of surveillance or endoscopic eradication in Barrett’s esophagus with high-grade dysplasia

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Population</th>
<th>Strategies</th>
<th>Most cost-effective strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hu 2016 (32)</td>
<td>65-year-old patients with HGD</td>
<td>Surveillance</td>
<td>RFA</td>
</tr>
<tr>
<td>Kastelein 2015 (33)</td>
<td>55-year-old men with HGD</td>
<td>None</td>
<td>RFA</td>
</tr>
<tr>
<td>Hur 2012 (34)</td>
<td>50-year-old patients with HGD</td>
<td>Surveillance</td>
<td>RFA</td>
</tr>
<tr>
<td>Boger 2010 (35)</td>
<td>64-year-old men with HGD</td>
<td>Esophagectomy</td>
<td>RFA</td>
</tr>
<tr>
<td>Pohl 2009 (36)</td>
<td>65-year-old men with early Barrett’s esophageal cancer</td>
<td>RFA</td>
<td>RFA</td>
</tr>
<tr>
<td>Inadomi 2009 (37)</td>
<td>50-year-old patients with HGD</td>
<td>None</td>
<td>RFA</td>
</tr>
</tbody>
</table>

HGD, high grade dysplasia; RFA, radiofrequency ablation; ND, non-dysplastic; BE, Barrett’s esophagus; LGD, low grade dysplasia; APC, argon plasma coagulation; PDT, photodynamic therapy.
Non-endoscopic screening for BE

Expansion of screening for BE will be expensive unless non-endoscopic tests are used. Non-sedated, office-based testing is possible with the Cytosponge™, an ingestible capsule comprised of compressed mesh attached to a string. The capsule is swallowed and the mesh expands in the stomach, obtaining cytologic sampling of the esophagus when the

Table 3 Cost-effectiveness of surveillance or endoscopic eradication for Barrett’s esophagus with low-grade dysplasia or no dysplasia

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Population</th>
<th>Strategies</th>
<th>HGD treatment</th>
<th>Most cost-effective strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kastelein 2015 (33)</td>
<td>55-year-old men with ND BE</td>
<td>No surveillance</td>
<td>None</td>
<td>ND BE: surveillance q5 years with RFA for HGD</td>
</tr>
<tr>
<td></td>
<td>55-year-old men with LGD</td>
<td>No surveillance</td>
<td>None</td>
<td>Surveillance every 3 years with RFA for HGD (WTP €35K); annual surveillance with RFA for HGD (WTP €80K)</td>
</tr>
<tr>
<td>Gordon 2014 (38)</td>
<td>50-year-old patients with BE</td>
<td>Surveillance every 2 years for ND BE and every 6 month for BE with LGD</td>
<td>RFA</td>
<td>No surveillance</td>
</tr>
<tr>
<td>Hur 2012 (34)</td>
<td>50-year-old patients with LGD</td>
<td>Surveillance</td>
<td>Surveillance</td>
<td>Initial RFA</td>
</tr>
<tr>
<td></td>
<td>50-year-old patients with ND BE</td>
<td>Surveillance</td>
<td>Surveillance</td>
<td>Surveillance with RFA for HGD</td>
</tr>
<tr>
<td>Das 2009 (39)</td>
<td>50-year-old men with ND BE</td>
<td>Surveillance ND BE every 3 years, LGD annually, HGD every 3 months</td>
<td>Surveillance, esophagectomy if high risk</td>
<td>N/A</td>
</tr>
<tr>
<td>Inadomi 2009 (37)</td>
<td>50-year-old patients with LGD</td>
<td>No surveillance</td>
<td>None</td>
<td>Ablation without surveillance</td>
</tr>
<tr>
<td></td>
<td>50-year-old patients with ND BE</td>
<td>No surveillance</td>
<td>None</td>
<td>Ablation without surveillance</td>
</tr>
</tbody>
</table>

ND, non-dysplastic; BE, Barrett’s esophagus; RFA, radiofrequency ablation; HGD, high grade dysplasia; LGD, low grade dysplasia; APC, argon plasma coagulation; MPEC, multipolar electrocoagulation.
String is withdrawn. The cells obtained in this manner are tested for the presence of trefoil factor 3, which is an immunohistochemical marker that has been demonstrated to have a sensitivity of 73.35% and specificity of 93.8% for BE (42). An economic analysis conducted by Benaglia et al. demonstrated that Cytosponge™ screening for BE with endoscopic mucosal resection and RFA for patients diagnosed with HGD is a cost-effective strategy. The cost-effectiveness of this approach is $15,000 per QALY gained compared with no screening, and is most cost-effective than screening with standard endoscopy (43).

Summary

Strategies to reduce mortality from EAC are evolving. We have an increasing understanding of the natural history of BE and its transformation to EAC, and our ability to stratify cancer risk is improving. The endoscopic treatment of dysplasia is also improving with increased effectiveness and reduced harms. The economic analyses discussed in this review unambiguously support endoscopic eradication therapy for patients with BE with HGD. Unfortunately, the management of LGD is not as straightforward due to the histopathological difficulty in the diagnosis of LGD and disparate estimates of the cancer risk. Patients with non-dysplastic BE are optimally managed with endoscopic surveillance and future efforts should be aimed at identifying the sub-group of non-dysplastic patients who possess an elevated risk of cancer and would benefit from endoscopic eradication.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


doi: 10.21037/tgh.2018.11.09

Cite this article as: Inadomi JM, Saxena N. Endoscopic surveillance or ablation for Barrett’s esophagus? Transl Gastroenterol Hepatol 2018;3:102.